Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Enhancing Efficiency in FAST-EU Clinical Trials: A New Era for Biomedical Research
Advancing EU Clinical Trial Efficiency Through FAST-EU Trials
The FAST-EU clinical trials initiative, launched by a coalition of National Competent Authorities (NCAs) and Ethics Committees across the European Union/Europ...
Advancements in Continuous Glucose Monitoring for Type 2 Diabetes Management
Advancements in CGM for Type 2 Diabetes Management
A recent JAMA Insights article, explores the integration of continuous glucose monitoring as a complementary tool to traditional hemoglobin A1c (HbA1c) an...
GLP-1RAs Psychiatric Care: Transforming Metabolic Management for Psychotropic Patients
Emerging Role of GLP-1 Receptor Agonists
In psychiatric care, GLP-1RAs offer a promising approach for managing weight gain induced by psychotropic medications, as detailed in this